{
    "info": {
        "nct_id": "NCT03937219",
        "official_title": "A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk",
        "inclusion_criteria": "* Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.\n* Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.\n* Measurable disease per RECIST 1.1 as determined by the Investigator. Measurable disease must be outside the radiation field if radiation therapy was previously administered.\n* Karnofsky Performance Status (KPS) ≥ 70%.\n* Adequate organ and marrow function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC including investigational agents.\n* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and stable for at least 4 weeks prior to randomization.\n* Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.\n* Administration of a live, attenuated vaccine within 30 days prior to randomization.\n* Uncontrolled, significant intercurrent or recent illness including, but not limited to serious cardiovascular disorders (including uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment), GI disorders associated with high risk for perforation or fistula formation, tumors invading GI tract, bowel obstruction, intra-abdominal abscess, clinically significant bleeding events, cavitating pulmonary lesions, or lesions invading major pulmonary blood vessels.\n* Other clinically significant disorders such as:\n\n  * Autoimmune disease that has been symptomatic or required treatment within the past two years from the date of randomization.\n  * Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization.\n  * Active infection requiring systemic treatment. Acute or chronic hepatitis B or C infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active myobacterial infection.\n  * Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to randomization.\n* Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization. Minor surgeries within 10 days prior to randomization. Subjects must have complete wound healing from major or minor surgery before randomization.\n* Any other active malignancy at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.",
                    "criterion": "renal cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "advanced (not amenable to curative surgery or radiation therapy)",
                                "metastatic (AJCC Stage IV)"
                            ]
                        },
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": "clear-cell component"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST 1.1 as determined by the Investigator. Measurable disease must be outside the radiation field if radiation therapy was previously administered.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST 1.1 as determined by the Investigator",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "per RECIST 1.1"
                        },
                        {
                            "requirement_type": "assessment",
                            "expected_value": "as determined by the Investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "Measurable disease must be outside the radiation field if radiation therapy was previously administered",
                    "criterion": "measurable disease location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "outside the radiation field"
                        },
                        {
                            "requirement_type": "conditional",
                            "expected_value": "if radiation therapy was previously administered"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky Performance Status (KPS) ≥ 70%.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance Status (KPS) ≥ 70%",
                    "criterion": "Karnofsky Performance Status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.",
            "criterions": [
                {
                    "exact_snippets": "Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database Consortium (IMDC) criteria.",
                    "criterion": "risk group for renal cell carcinoma (RCC)",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": [
                                "intermediate",
                                "poor"
                            ]
                        },
                        {
                            "requirement_type": "definition system",
                            "expected_value": "International Metastatic RCC Database Consortium (IMDC) criteria"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Other clinically significant disorders such as:",
            "criterions": [
                {
                    "exact_snippets": "Other clinically significant disorders",
                    "criterion": "clinically significant disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Autoimmune disease that has been symptomatic or required treatment within the past two years from the date of randomization.",
            "criterions": [
                {
                    "exact_snippets": "Autoimmune disease that has been symptomatic or required treatment within the past two years from the date of randomization.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment_required_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and stable for at least 4 weeks prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Known brain metastases or cranial epidural disease",
                    "criterion": "brain metastases or cranial epidural disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless adequately treated with radiotherapy and stable for at least 4 weeks prior to randomization",
                    "criterion": "brain metastases or cranial epidural disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "adequately treated with radiotherapy"
                        },
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy for bone metastasis within 2 weeks ... prior to randomization",
                    "criterion": "radiation therapy for bone metastasis",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other radiation therapy within 4 weeks prior to randomization",
                    "criterion": "other radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC including investigational agents.",
            "criterions": [
                {
                    "exact_snippets": "Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC including investigational agents.",
                    "criterion": "prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Known history of COVID-19 unless the subject has clinically recovered from the disease at least 30 days prior to randomization",
                    "criterion": "history of COVID-19",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "recovery_time_since_COVID-19",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "Concomitant anticoagulation with oral anticoagulants",
                    "criterion": "concomitant anticoagulation with oral anticoagulants",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... platelet inhibitors",
                    "criterion": "concomitant anticoagulation with platelet inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization.",
            "criterions": [
                {
                    "exact_snippets": "Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) ... within 14 days of randomization.",
                    "criterion": "systemic corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any condition requiring systemic treatment with ... other immunosuppressive medications within 14 days of randomization.",
                    "criterion": "systemic immunosuppressive medication treatment",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other active malignancy at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.",
            "criterions": [
                {
                    "exact_snippets": "Any other active malignancy at time of randomization",
                    "criterion": "active malignancy (other than index cancer)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of another malignancy within 3 years prior to randomization that requires active treatment",
                    "criterion": "diagnosis of another malignancy within 3 years prior to randomization requiring active treatment",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "active_treatment_required",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled, significant intercurrent or recent illness including, but not limited to serious cardiovascular disorders (including uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment), GI disorders associated with high risk for perforation or fistula formation, tumors invading GI tract, bowel obstruction, intra-abdominal abscess, clinically significant bleeding events, cavitating pulmonary lesions, or lesions invading major pulmonary blood vessels.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled, significant intercurrent or recent illness",
                    "criterion": "intercurrent or recent illness",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiovascular disorders",
                    "criterion": "cardiovascular disorders",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "blood pressure systolic",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "blood pressure diastolic",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "despite optimal antihypertensive treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "GI disorders associated with high risk for perforation or fistula formation",
                    "criterion": "GI disorders with high risk for perforation or fistula formation",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "tumors invading GI tract",
                    "criterion": "tumors invading GI tract",
                    "requirements": [
                        {
                            "requirement_type": "invasion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bowel obstruction",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intra-abdominal abscess",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant bleeding events",
                    "criterion": "bleeding events",
                    "requirements": [
                        {
                            "requirement_type": "significance",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "cavitating pulmonary lesions",
                    "criterion": "cavitating pulmonary lesions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lesions invading major pulmonary blood vessels",
                    "criterion": "lesions invading major pulmonary blood vessels",
                    "requirements": [
                        {
                            "requirement_type": "invasion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of a live, attenuated vaccine within 30 days prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 30 days prior to randomization.",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization. Minor surgeries within 10 days prior to randomization. Subjects must have complete wound healing from major or minor surgery before randomization.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 4 weeks prior to randomization",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Minor surgeries within 10 days prior to randomization",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects must have complete wound healing from major or minor surgery before randomization",
                    "criterion": "wound healing status",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic treatment. Acute or chronic hepatitis B or C infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active myobacterial infection.",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic treatment",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Acute or chronic hepatitis B or C infection",
                    "criterion": "hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness",
                    "criterion": "HIV or AIDS-related illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known positive test for tuberculosis infection where there is clinical or radiographic evidence of active myobacterial infection",
                    "criterion": "tuberculosis infection with clinical or radiographic evidence of active myobacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "evidence of active myobacterial infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}